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INTRODUCTION 
Over the past several years there has been a dramatic 
increase in bowel diseases. Approximately one third of 
patients with mucosal ulcerative colitis undergo operative 
treatment.1 In recent years, colon targeted delivery systems 
have been the focus point of formulation laboratories 
because the colon is considered as a suitable site for the 
delivery of both conventional and labile molecules, and it 
is also a site for some specific diseases, such as, ulcerative 
colitis, crohn’s disease, bowel cancer, some infections, and 
constipation, which require local delivery of the drug(s).2 
Colonic drug delivery may be achieved by either oral or 
rectal administration. Rectal dosage forms (enemas and 
suppositories), are not always much effective due to high 
variability in the distribution of drug administered by this 
route.3 The major obstacle with the delivery of drugs by 
oral route to the colon is the absorption and degradation of 
the drug in the upper part of gastrointestinal tract (GIT) 
which must be overcome for successful colonic drug 
delivery.4 
Various approaches have been used for oral delivery of 
drug(s) to the colon which includes time dependent 
delivery, pH- dependent systems and bacteria- dependent 
delivery. The pH dependent systems exploit the generally 
accepted view that pH of human gastrointestinal (GI) tract 
increases progressively from the stomach (pH 2-3), small 
intestine (pH 6.5-7) to the colon (7.0-8.0). Taking 
advantage of the highest pH value of the colon content, the 
dosage form containing the active drug in the core is 
coated with pH dependent material which dissolves at the 
pH of colon. But recent studies using sensitive and reliable 
equipments contradict the traditional view and provide 
evidence of a fall in pH at the GI region between ileum 
and colon.5,6 Apparently, colon has a lower pH value (6.5) 
than the small intestine (7.0-7.8), and the jejunal region of 
some individuals has a higher pH range (6.1-7.2) than the 
small intestine or colon of other individuals.2 
Ulcerative colitis is the anti inflammatory disease of the 
colonic mucosa which is restricted to large intestine and is 
usually treated with salicylates or glucocorticoids. 
However, during periods of remission mesalamine is the 
drug of choice. In this case it is desirable to localize the 
release of mesalamine to the afflicted site in the colon.7-9 
Thus, Mesalamine was used as a model drug in the present 
study. Mesalamine is an anti inflammatory drug, for oral 
adminsteration in the treatment of diseases of colon 
(ulcerative colitis, crohn’s disease, carcinomas and 
infections) whereby high local concentration can be 
achieved while minimizing side effects that occur because 
of release of drugs in the upper GIT or unnecessary 
systemic absorption.10 
OBJECTIVES  
The objective of this study is to develop formulations 
using a combination of time and pH dependent system for 
delivering mesalamine to the colon and to sustain the 
release of the drug using various grades of HPMC (HPMC 
K-4M and HPMC K-15M) so as to reduce the dosing 
frequency of the drug and to demonstrate its site specificity 
in the colon. Effect of polymer concentration and the 
superdisintegrant concentration was also investigated.  
Methacrylic acid copolymers such as Eudragit S-100 and 
Eudragit L-100 have been commonly used as pH 
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dependent polymers for coating solid dosage forms 
(because of their solubility at pH 6.0 or higher and 7.0 or 
higher respectively), none of them is suitable for use alone 
for coating of solid dosage forms that would start releasing 
the drug specifically at pH 6.4 which is generally 
considered as the suitable pH for colon targeted drug 
delivery.
11-13 
A major drawback of Eudragit coated pH 
dependent formulation is premature release of drug in 
small intestine.14 
MATERIALS AND METHODS 
 Mesalazine (5-amino salicylic acid) was obtained from 
Hi-media Pvt Ltd., Mumbai. HPMC K-4M and HPMC K-
15M were obtained as free gift sample from Colorcon Asia 
Pvt. Ltd., Goa. Crosspovidone, Eudragit L-100 and S-100 
were obtained from Yarrowchem products, Mumbai. 
Starch and magnesium stearate were obtained from S.d 
fine chem., Mumbai and Lactose was obtained from 
Qualikems fine chemicals Ltd, New Delhi. All reagents 
and solvents used were of analytical grade satisfying 
pharmacopoeial standards. 
1) ANALYTICAL METHOD VALIDATION 
1.1. Linearity and Range
15 
Aliquots of different concentration of Mesalazine were 
prepared upto highest concentration, till linearity was 
observed and absorbance was recorded at 302 nm for 
acidic media, 331.60 nm and 331.70 nm for phosphate 
buffer of pH 6.8 and 7.4 respectively. 
1.2. Limit of Detection (LOD)
15,16 
The LOD of Mesalazine was determined in placebo 
solution. It was based on the standard deviation of the 
blank. It was computed from the calibration graphs using 
the equation 3.3σ/s where σ is the standard deviation of 
three blank determinations and s is the slope of calibration 
curve. The detection limit of an individual analytical 
procedure is the lowest amount of analyte in a sample 
which can be detected but not necessarily quantitated as an 
exact value. 
1.3. Limit of Quantitation
15,16 
The quantitation limit is a parameter of quantitative assays 
for low levels of compounds in sample matrices, and is 
used particularly for the determination of impurities and/or 
degradation products. It was computed from the calibration 
graphs using the equation 10σ/s, where σ is the standard 
deviation of three blank determinations and s is the slope 
of calibration curve. 
2) FOURIER TRANSFORM INFRARED 
SPECTROSCOPY (FTIR) STUDY 
The IR absorption spectrum of the pure drug was taken in 
the range of 4000-450 cm using KBr pellet method .The 
major peaks were reported for evaluation of purity. 
Observed peaks are similar to reported peaks of 
Mesalazine. 
 
Figure 1: FTIR spectra of Mesalazine 
Table 1: Interpretation of FTIR Spectra of Mesalazine: 
S.No Functional Group Peaks Observed 
1) C=C stretch of the aromatic group; 
N-H bond scissoring 
1621.24 
2) C-H stretch of the aromatic group 2976.52 
3) C-C stretching mode 1487.79 
4) O-H deformation of the hydroxyl groups 1582,1487,1450 
5) C-O stretching mode 1194.90 
6) In plane bending mode 1192.24-1265.96 
7) C-H bond out of plane bending mode; Ring 
deformation of the aromatic group 
685.01 
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Figure 2: FTIR Spectra of Mesalazine + HPMC K-4M 
 
Figure 3: FTIR Spectra of Mesalazine + HPMC K-15M 
 
Figure 4: FTIR Spectra of Mesalazine + Crosspovidone 
 
Figure 5: FTIR Spectra of Mesalazine + Lactose 
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3) PREPARATION OF CORE TABLETS 
All the ingredients were weighed separately. Mesalazine, 
lactose, crosspovidone and HPMC (K-4M, K-15M either 
alone or in combination) were passed through the 16 # 
sieve and thoroughly mixed and then granulated using 
starch solution (1% in iso propyl alcohol) as a binder. The 
granules so obtained were dried at 50-60 °C for 2 hr in the 
oven. These granules were lubricated with flow promoters 
like magnesium stearate. The flow properties of the 
granules were determined. The lubricated granules were 
compressed into tablets (each 600 mg) using using 12mm 
concave-faced punch of 10 station Rimek compression 
machine. Weight variation, hardness, friability, and 
disintegration test were performed for the core tablets. 
 
Table 2: Composition of Different Core Tablets of Mesalazine 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 
Mesalazine 400 400 400 400 400 400 400 400 
HPMC K4M 120 120 110 110 10 10 60 60 
HPMC K 15M - - 10 10 110 110 60 60 
Magnesium stearate 2 2 2 2 2 2 2 2 
Starch (1%) q.s q.s q.s q.s q.s q.s q.s q.s 
Crosspovidone 7.2 
(1.2%) 
14.4 
(2.4%) 
7.2 
(1.2%) 
14.4 
(2.4%) 
7.2 
(1.2%) 
14.4 
(2.4%) 
7.2 
(1.2%) 
14.4 
(2.4%) 
Lactose 70.8 63.6 70.8 63.6 70.8 63.6 70.8 63.6 
* 
All quantities are expressed in milligrams 
4) EVALUATION OF CORE TABLETS 
4.1. Precompressional studies 
4.1.1. Flow Properties of Granules 
4.1.1.1. Apparent Bulk density:
17 
Apparent bulk density was determined by placing pre-
sieved granules into a graduated cylinder and measuring 
the volume and weight as it is. It was calculated by using 
formula 
Bulk density = Mass / volume 
4.1.1.2. Tapped density: 17                                   
Weighed sample of granules was transferred to a graduated 
cylinder and was tapped for a fixed number of taps (100). 
Tapped density was calculated by formula given in 
equation 
Tapped Density = Weight of granules / Tapped volume 
4.1.1.3. Hausner’s Ratio: 18 
The Hausner’s ratio is a number that is correlated to the 
flowability of a powder or granular material. It is 
calculated by formula given in equation 
Hausner’s Ratio = Tapped Density / Bulk Density 
4.1.1.4. Compressibility Index: 
18 
It is a simple test to evaluate bulk density and tapped 
density of granules and the rate at which it is packed down. 
The formula for Carr’s index was given in equation 
Carr’s Index (%) = [(Tapped density-Bulk 
Density) x100]/Tapped Density 
4.1.1.5. Angle of Repose:
19 
The angle of repose of blend was determined by the fixed 
funnel method. The accurately weighed granules were 
taken in the funnel. The height of the funnel was adjusted 
in such a way that the tip of the funnel just touched the 
apex of the blend. The blend was allowed to flow through 
the funnel freely onto the surface. The diameter of the 
powder cone was measured and angle of repose was 
calculated using the formula given in equation 
Tan θ = h/r 
Where, h and r are the height and radius of the powder 
cone 
4.2. Post Compressional Studies 
4.2.1. Shape and Appearance: 
20 
Tablets were examined under a lens for the shape of the 
tablet, and colour was observed by keeping the tablets in 
light. 
4.2.2. Hardness: 
21 
Monsanto hardness tester was used for the determination 
of the hardness.  The tablet to be tested was held between a 
fixed and a moving jaw and reading of the indicator was 
adjusted to zero. The force applied to the edge of the tablet 
was gradually increased by moving the screw knob 
forward .until the tablet broke. The reading was noted from 
the scale which indicates the pressure required in kg or lb 
to break tablets. 
4.2.3. Thickness:
20 
The crown-to-crown thickness of ten tablets from each 
batch was determined using vernier caliper. The thickness 
variation limits allowed are ± 5% of the size of the tablet. 
4.2.4. Weight Variation: 
20 
Weight variation study was carried out as per USP. 
Twenty tablets were randomly selected from each batch 
weighed individually. The average weight and standard 
deviation was calculated. 
4.2.5. Friability:
22,23 
Roche friabilator (Electrolab Mumbai) was used for testing 
the friability of prepared tablets. Twenty tablets were 
weighed accurately and placed in the friabilator and 
rotated at 25 rpm for a period of 4 min. Tablets were 
dedusted using soft muslin cloth and weighed again. 
Percentage weight loss was determined by using following 
formula.  
% Friability =      [(Initial weight- Final weight)/ Initial 
weight] X 100 
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4.2.6. Uniformity of Drug Content:
24 
For determination of drug content, five tablets from each 
formulation were triturated using mortar and pestle. An 
accurately weighed powder equivalent to 400 mg of drug 
was taken in 100 ml volumetric flask and diluted with 
sufficient amount of phosphate buffer of pH 6.8 up to 
mark. Then the sample was sonicated for 1 hr and filtered. 
An aliquot of the filtrate was diluted suitably and analyzed 
spectrophotometrically at 331.60 nm against blank. The 
test was done in triplicate and average drug content was 
estimated. 
5) PREPARATION OF COATING SOLUTION 
Table 3: Trials of Coating Using Combination of Eudragit S-100 and L-100 
Ingredient Function F4 F5 F6 
Eudragit S-100 Enteric Polymer 16 16 16 
Eudragit L-100 Enteric Polymer 16 16 16 
Diethyl phthalate Plasticizer 4 4 4 
Acetone Solvent 250 250 250 
IPA Solvent 250 250 250 
% coating  8% 10% 12% 
*Quantity in grams 
 
Parameter Value 
Inlet Air Temperature = 40-450C 
Exhaust Temperature = 30-350C 
Bed Temperature = 380C 
Atomization (bar) = 2 
Spray rate (gm/min) = 10 
Pan RPM = 10 
6) EVALUATION OF ENTERIC COATED TABLETS 
6.1. Hardness Test:
21 
 The hardness of the coated tablets was measured using 
same procedure as described earlier with the help of 
Monsanto hardness tester. The hardness of various 
formulations was shown in table 9. 
6.2. Weight Variation Test:
20 
 The weight variation test was carried out for the coated 
tablets using the same procedure as described earlier and 
the results were reported in the table 9. 
6.3. In-vitro Disintegration Test of Coated Tablets:
22 
Tablet disintegration was carried by placing one tablet in 
each tube of the basket and top portion of the each tube 
was closed with disc. Tablets were firstly tested in 0.1N 
HCl for 2 h (simulated gastric transit time) to see the 
damage to the coat. Afterwards, tablets were tested in the 
phosphate buffer pH 6.8 (simulated colonic pH) till the 
coating dissolved. Temperature in each case was kept at 
37±0.5°C. Disintegration time was reported in min. The 
time taken for complete disintegration of the tablet with no 
palpable mass remaining in the apparatus was measured. 
The experiment was carried out in triplicate. 
6.4. Lag Time Profile:
25 
Time dependent systems are formulated to undergo a lag 
time of predetermined span of time of no release, followed 
by a rapid and complete release of loaded drug. Lag time is 
the time required to transit from the mouth to the colon.  
6.5. In-vitro Dissolution Profile of Mesalazine Coated 
Tablets: 
 In vitro drug release studies for the prepared tablets were 
conducted for a period of 12 hours using USP type-II 
(Paddle) dissolution apparatus (Electro lab, Mumbai.) at 
370.5oC and 75 rpm speed using pH 1.2 buffer for initial 
2 h, phosphate buffer of pH 7.4 up to 3 h as and phosphate 
buffer of pH 6.8 for 7 h as dissolution medium. At 
predetermined interval of time, 10 ml of sample was 
withdrawn from the dissolution medium and replaced with 
fresh medium to maintain the volume constant. After 
filtration and appropriate dilution, the sample solutions 
were analyzed at 302 nm (acidic media) and 331.70nm 
(basic media) for Mesalazine by a UV-visible 
spectrophotometer. The amount of drug present in the 
samples was calculated and the results were reported in 
tables 10(a) and 10(b).  
7) COMPARISON OF THE BEST FORMULATION 
WITH THE MARKETED FORMULATION 
The best formulation was selected on the basis of the 
release profile and lag time and compared with the 
marketed formulation (Asacol). 
8) SIMILARITY FACTOR 
26-28 
The similarity factor (f2) is a logarithmic transformation of 
the sum-squared error of differences between the test Tt 
and reference products Rt over all time points. It represents 
closeness of two comparative formulations. Generally 
similarity factor in the range of 50-100 is acceptable 
according to US FDA. Equation for calculation of 
similarity factor: 
f2 = 50 X log {[1+ (1/n) ∑t=1 * n (Rt-Tt)
2
]
-0.5
 *100} 
Rt and Tt are the cumulative percentage dissolved at each 
of the selected n time points of the reference and test 
product respectively. 
9) STATISTICAL ANALYSIS 
The data was analyzed by using one way Analysis of 
Variance (ANOVA) followed by Tukey and Dunnett tests 
by using Graph pad prism software. The value of p<0.05 
was considered to be statistical significant.  
10) RELEASE KINETIC OF SELECTED 
FORMULATION 
29-31
 
To examine the drug release kinetics and mechanism, the 
cumulative release data were fitted to models representing. 
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 Zero order (cumulative % drug release v/s. time). 
 First order (log cumulative % drug remaining v/s. time). 
 Higuchi model (cumulative % drug release v/s. Square root 
of time). 
 Korsemeyer Peppas model (log cumulative % drug release 
v/s. log time).  
11) STABILITY STUDY 
The selected batch (F2) was kept at 40°C with 75% RH 
and the samples were withdrawn at 30, 60 and 90 days for 
physical and in-vitro evaluation of drug release. 
Table 4: Stability Study 
Parameter Initial 1 month 
(40°C/75%RH) 
2 month 
(40°C/75%RH) 
3 month 
(40°C/75%RH) 
Description Yellowish brown, 
round shaped 
Same Same Same 
Average weight (mg) 681.10 681.10 681.10 681.10 
Hardness (kg/cm
2
) 6.61 6.61 6.61 6.61 
Dissolution Study 
0 0 0 0 0 
1 0 0 0 0 
2 0 0 0 0 
3 0 0 0 0 
4 8.52 7.99 7.85 6.90 
5 18.45 17.85 16.72 16.49 
6 40.56 39.71 38.89 35.66 
7 50.42 52.02 52.11 47.02 
8 61.05 60.28 60.25 59.77 
9 69.58 68.66 67.41 68.98 
10 79.23 78.59 77.90 78.86 
11 89.42 89.42 89.45 89.31 
12 96.53 95.49 95.46 95.90 
 
6) RESULTS AND DISCUSSION 
6.1. ANALYTICAL METHOD VALIDATION 
Table 5: Characteristics and Validation Parameters of Mesalazine 
Validation Parameter Values 
 In 0.1N HCl In PB pH 6.8 In PB pH 7.4 
λmax (nm) 302 331.60 331.70 
Linearity equation Y= 0.046x+0.021 Y= 0.086x+0.038 Y= 0.085x+0.018 
Range (µg/ml) 1-10 1-10 1-10 
Intercept (c) 0.021 0.038 0.018 
R
2 
value 0.993 0.995 0.996 
LOD (µg/ml) 0.220 0.216 0.218 
LOQ (µg/ml) 0.685 0.673 0.688 
The low values of LOD and LOQ indicated that the method was sensitive and validated. 
6.2. EVALUATION OF CORE TABLETS 
6.2.1. Precompressional Studies  
6.2.1.1. Flow Properties of Granules 
Table 6: Micromeritic properties of granules 
Formulation 
code 
Bulk density 
(gm/ml) 
Tapped 
density(g/ml) 
Carr’s index (%) Hausner’s ratio Angle of repose 
(Ɵ) 
F1 0.366 0.497 26.35 1.355 38.2 
F2 0.364 0.494 26.31 1.357 37.5 
F3 0.361 0.490 26.33 1.357 38.6 
F4 0.367 0.499 26.45 1.359 35.0 
F5 0.362 0.494 26.72 1.364 32.9 
F6 0.367 0.491 25.25 1.337 33.4 
F7 0.365 0.496 26.41 1.358 34.6 
F8 0.366 0.492 25.60 1.344 37.4 
*All values are expressed as mean ± SD. n=3. 
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From the results of carr’s index and hausner’s ratio, it was 
concluded that except formulations F6 and F8, all the 
formulations possess poor flowability of granules. 
Formulations F6 and F8 were having passable flow of 
granules. From the results of angle of repose, it was 
concluded that except granules of F5 and F6, all other 
formulations possess poor flow. F5 and F6 were having 
passable flow.  
6.2. Post Compressional Studies: 
6.2.1. Shape and Appearance 
Tablets showed standard concave surfaces with circular 
shape. Tablets were light brownish in color. 
6.2.2. Physicochemical Evaluation of Core Tablets 
Table 7: Physicochemical Evaluation of Core Tablets of Mesalazine 
Formulation 
Code 
Thickness
*
 (mm) Weight*** 
(uncoated 
tablets) 
(mg) 
Hardness
*
 
(uncoated 
tablets) 
(kg/cm
2
) 
Content 
uniformity
*
 (%) 
Friability
**
 (%) 
F1 5.41±0.771 600.20±1.64 5.8±0.37 99.97±0.556 0.17 
F2 5.30±0.771 600.25±1.48 5.74±0.15 100.15±0.56 0.15 
F3 5.10±0.773 600.15±1.56 6.08±0.13 100.18±0.74 0.20 
F4 5.00±0.771 600.10±1.29 6.1±0.29 99.02±0.950 0.21 
F5 5.12±0.774 600.05±1.3 6.36±0.15 101.04±0.68 0.12 
F6 5.16±0.772 599.05±1.19 6.62±0.11 99.57±0.31 0.14 
F7 5.24±0.772 600.25±1.4 6.27±0.24 95.25±0.25 0.17 
F8 5.10±0.771 600.10±1.29 6.23±0.19 96.75±0.95 0.16 
*All values are expressed as mean ± SD, *n=3, ***n=20, ** n=6. 
 
Graph 1: Thickness of the Formulation Batches (F1-F8) 
 
Graph 2: Hardness of the Formulation Batches (F1-F8) 
 
Graph 3: Percent Drug Content of the Formulation Batches (F1-F8) 
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Graph 4: Friability of the Formulation Batches (F1-F8) 
6.3. TRIALS OF COATING WITH COMBINATION 
OF EUDRAGIT L-100 AND EUDRAGIT S-100 IN 
COMBINATION:  
 The cumulative in-vitro release study was carried out 
using USP dissolution apparatus type II. Cumulative % 
drug release after 7 hrs was found to be 45.28%, 50.11% 
and 38.17% for formulation F4, F5 and F6 respectively. 
The release before completion of lag time was found to be 
16.25%, 19.33% and 12.14% for formulation F1, F2 and 
F3 respectively. 
The results obtained in the in-vitro drug release study are 
tabulated in Table 8. The cumulative percentage of 
Mesalazine released as a function of time for all the 
formulations are shown in graph 5. Coating of tablets with 
Eudragit L-100: Eudragit S-100 in combination showed 
the lag time of nearly 5 hrs before burst effect. From the 
result, concluded that the combination of Eudragit L-100: 
Eudragit S-100 can be successfully utilized to create 
desired release profile similar to the targeted release 
profile in future study. 
 
Table 8: In-vitro Release Profile During Trials of Coating With Eudragit S-100 and L- 100 in Combination: 
Dissolution 
media 
Time 
(hours) 
Cumulative % drug release 
 
 
0.1 N HCl 
 F4 F5 F6 
0 0 0 0 
1 0 0 0 
2 0 0 0 
 
PB pH 7.4 
3 0 0 0 
4 7.36 7.19 6.13 
5 16.25 15.33 12.14 
 
 
 
PB pH 6.8 
6 35.23 42.19 26.09 
7 45.28 50.11 38.17 
8 57.54 61.14 45.82 
9 66.35 70.72 56.77 
10 71.86 75.4 67.59 
11 84.63 81.97 75.32 
12 94.82 95.66 84.57 
 
 
Graph 5: In-vitro Release Profile of Formulations (F4-F6) During Trials of Coating with Eudragit S- 100 and L- 100 
in Combination 
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From the results, we have seen that 10% enteric coating 
gave us more appropriate results as the release of drug at 
pH 7.4 was less and the drug release at pH 6.8 was more, 
i.e the drug release was more in the colonic region. While 
using the 8% enteric coating, more drug was degraded in 
the small intestine. Also, using the 12% coating, the 
release of drug in the pH 6.8 (colonic pH) was very less as 
compared to the 8% and 10% enteric coating. So, the 
optimized formula of coating consisted of 10% coating of 
tablets. 
6.4. EVALUATION OF ENTERIC COATED 
TABLETS 
6.4.1. In- Process Quality Control Tests of Enteric 
Coated Tablets 
Table 9: In Process Quality Control Tests Conducted After Coating of Tablets 
Formulation code Hardness* (kg/cm²) Disintegration time** (min) Weight***(coated tablets) (mg) 
F1 6.4±0.30 225.89±1.61 679.33±2.35 
F2 6.61±0.17 218.65±1.98 681.10±2.66 
F3 7.13±0.21 223.69±1.98 680.19±2.15 
F4 7.15±0.34 219.76±3.50 679.76±2.91 
F5 7.25±0.29 231.18±2.87 679.71±2.93 
F6 7.36±0.41 230.82±2.25 680.38±3.84 
F7 7.51±0.53 235.45±1.18 681.10±2.6 
F8 7.42±0.82 235.64±2.54 685.40±1.75 
*All values are expressed as mean ± SD, *n=3, **n=6, ***n = 20. 
6.4.2. Lag Time Profile 
The lag time profile versus time graph is plotted in graph 6. From the results, it was concluded that F2 and F5 were having 
sufficient lag time of 3.5 hours. The greater the lag time, more will be the time taken by the dosage form to release the 
drug. 
 
Graph 6: Lag Time Versus Number of Batches 
6.4.3. In-Vitro Dissolution Profile of Coated Tablets Using Optimized Formula of Coating 
The in-vitro release study was carried out using USP dissolution apparatus type II. The results obtained in the in-vitro drug 
release study are tabulated in table 10(a) and table 10(b). The cumulative percentage release of Mesalazine as a function of 
time for all the formulations is shown in graph 7.  
Table 10 (a): In-vitro Drug Release Study of Mesalazine Coated Tablets (F1-F4) 
Dissolution media Time (hours) Cumulative % drug release 
 
 
0.1 N HCl 
 F1 F2 F3 F4 
0 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
1 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
2 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
 
PB pH 7.4 
3 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
4 6.74±0.577 8.52±2.901 6.45±0.991 7.86±0.831 
5 17.21±1.352 18.45±2.882 16.59±1.034 17.59±0.621 
 
 
 
PB pH 6.8 
6 33.45±1.212 40.56±2.967 30.22±1.905 31.94±0.953 
7 45.45±2.438 50.42±2.901 40.55±2.734 41.66±2.11 
8 56.31±2.516 61.05±2.942 48.50±2.893 50.59±1.89 
9 65.41±1.243 69.58±2.79 56.37±2.935 59.17±2.99 
10 72.90±2.155 79.23±2.91 65.28±2.962 70.31±2.345 
11 82.19±1.501 89.42±2.83 73.01±2.994 80.82±2.575 
12 91.25±2.347 96.53±2.84 82.54±2.982 90.25±2.341 
*All values are expressed as mean± S.D 
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Table 10(b): In-vitro Drug Release Study of Mesalazine Coated Tablets (F5-F8)  
Dissolution 
media 
Time 
(hrs) 
Cumulative % drug release 
 
 
0.1 N HCl 
 F5 F6 F7 F8 
0 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
1 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
2 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
 
PB pH 7.4 
3 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
4 6.01±2.212 6.12±1.665 7.04±0.73 8.12±2.89 
5 12.05±0.65 14.47±1.36 17.59±1.034 15.23±2.91 
 
 
 
PB pH 6.8 
6 25.18±1.34 26.91±1.83 34.85±1.902 34.86±2.971 
7 33.91±1.28 34.40±2.10 41.62±1.689 51.49±2.995 
8 40.89±2.30 43.17±2.81 48.92±2.986 63.81±2.982 
9 47.81±2.76 51.55±2.58 53.28±1.901 70.56±2.884 
10 56.53±2.94 62.09±2.73 65.47±2.999 79.38±2.978 
11 60.44±2.95 68.91±2.47 79.58±1.791 87.78±2.895 
12 66.40±2.85 70.44±2.78 86.34±1.902 91.27±2.794 
*All values are expressed as Mean±S.D 
 
Graph 7: Effect of Polymer Level on In-vitro Release of Mesalazine From Enteric Coated Tablets (F1-F8) 
The results obtained were in agreement with the fact that 
formulations having higher percentage of HPMC K15M as 
a matrix former show much more retardation of drug 
release as compared to the formulations having lower 
percentage of HPMC K15M. Formulation F5 and F6 show 
least amount of drug release in dissolution study 
illuminating the effect of HPMC K15M concentration in 
the formulations.  
Reason: Presence of HPMC K15M forms a much more 
viscous layer around the tablet allowing less seepage of 
fluid into the tablet to prolong the drug release. Higher 
concentration of HPMC K15M provides gel layer which 
was more viscous as compared to that formed by lower 
concentration of HPMC K15M.  
Instead of higher concentration of HPMC K15M in the 
formulations F5 and F6, drug release values were almost 
nearer to the release values obtained from formulations F3 
and F4 which were having lower concentration of HPMC 
K15M.  
Reason: This was due to the higher molecular weight of 
the polymer. Owing to higher molecular weight, polymer 
chains were also bulkier in nature requiring more time for 
their unwinding by solvent molecules leading to delay in 
instant swelling of the polymer. This delay was responsible 
for the higher drug release from the formulations having 
higher concentration of HPMC K15M. 
Effect of Polymer Type and Concentration on Drug 
Release Behaviour: 
From the results of in vitro dissolution studies, it was clear 
that drug release depends upon the type of polymer and 
concentration of polymer. Drug release was found to be 
higher in case of formulations based on HPMC K4M.  
Reason: Being more viscous in nature, HPMC K-15M 
reduces the seepage of dissolution media into tablet core, 
hence sustain the release of drug. Delay in drug release 
was also owing to the enormous swelling potential of 
HPMC K15M which led to increase in diffusion path 
length. Dissolution results in pH 6.8 medium were also in 
correlation with above explanation. 
Effect of Superdisintegrant Concentration on Drug 
Release Behaviour: 
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Formulations having higher concentration of 
crosspovidone showed greater drug release as compared to 
that having lower concentration in the matrix of tablets. 
This was also clear from the comparison between 
dissolution results of formulations F1 and F2, F3 and F4, 
F5 and F6 followed by F7, F8 in dissolution medium of pH 
6.8. 
Reason: Increased drug release in formulations containing 
higher amount of superdisintegrant was due to the 
formation of pores and cavities in the matrix of tablets. 
Seepage of the dissolution medium in the matrix of tablets 
allows rapid swelling of tablet to provide burst effect. 
Swelling of the tablet depends upon the concentration of 
superdisintegrant in the formulation; higher amount of 
superdisintegrant provides higher swelling. But presence 
of rate controlling hydrophilic polymers do not allows 
drug to be released at rapid rate and sustained the release 
of drug. Due to this reason the drug release of formulations 
F2, F4, F6 and F8 is more than F1, F3, F5 and F7. 
6.5. COMPARISON OF THE OPTIMIZED 
FORMULATION WITH THE MARKETED 
FORMULATION 
From the in-vitro dissolution studies shown in table 10 (a) 
and 10(b), it was obvious that formulation F2 achieved 
more than 95% of the drug release in the time period and it 
had the lag time of 3.5 hours. So, it was best fitted to be 
called as optimized formulation. While the release of the 
marketed formulation was upto 63.449% in the small 
intestine this is because of the enteric coating using 
Eudragit S-100 alone. So there was a premature release of 
drug in small intestine.  
Moreover, 100% release of the drug was shown by the 
marketed formulation in 8 hours. While the formulation 
F2, being the sustained release formulation released the 
drug upto 12 hours. 
The in-vitro release profiles of both the optimized 
formulation, F2 and the marketed formulation, M1 are 
plotted in graph 8. 
 
Graph 8: Comparison of the Marketed Formulation (M1) and the Best Formulation (F2) 
6.6. SIMILARITY FACTOR 
The result of similarity factor is 20.125. Because the value 
of similarity factor is less than 50 so, it was concluded that 
there was a significant difference between dissolution 
profiles of optimized formulation and the marketed 
formulation. Because the dissolution profiles are 
considered to be similar when similarity factor (f2) is 
between 50 and 100.  
6.7. STATISTICAL EVALUATION  
From ANOVA all the results were expressed as Mean ± 
Standard Error. The data was analyzed by using one way 
Analysis of Variance (ANOVA) followed by Tukey and 
Dunnett tests by using Graph pad prism software. The 
value of p<0.05 was obtained and we conclude that all the 
values were statistically significant.  
Table 11: Calculation of ANOVA: Single Factor 
Batch Analysis of 
variance 
SS df MS F P-value Fcrit 
F1 Between groups 5937.928 1 5937.928 9.830951 0.004489 4.259677 
F2 Between groups 7303.338 1 7303.338 10.53471 0.003438 4.259677 
F3 Between groups 4485.734 1 4485.734 9.399612 0.005304 4.259677 
F4 Between groups 5328.472 1 5328.472 9.543051 0.005016 4.259677 
F5 Between groups 2825.071 1 2825.071 8.507464 0.007556 4.259677 
F6 Between groups 3462.923 1 3462.923 8.184894 0.006679 4.259677 
F7 Between groups 4893.375 1 4893.375 4.58037 0.004944 4.259677 
F8 Between groups 6930.779 1 6930.779 10.19862 0.003901 4.259677 
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6.8. KINETICS OF DRUG RELEASE 
The value of release exponent (n) was found to be a 
function of polymer used and the physicochemical 
property of a drug molecule itself. Kinetic results revealed 
that, all the formulations followed zero order kinetics as 
correlation coefficient (r2) values (0.919-0.953) are higher 
than that of first order release kinetics. The prepared 
tablets showed supercase-II transport release, as the values 
of release exponent (n) lies between 2.076-2.213 with 
correlation coefficient (r2) values upto 0.952, indicating 
that erosion of polymeric chain was involved in the release 
process.31 
 
Table 12: Regression Analysis (R
2
) of Release Data Based on Best Curve-Fitting Method for Different Formulations 
of Mesalazine Tablets (n=3) 
Formulation Zero order First Order Higuchi Korsemeyer Peppas 
n R
2
 n R
2
 n R
2
 n R
2
 
F1 8.646 0.950 -0.080 0.851 30.29 0.781 2.213 0.924 
F2 9.280 0.952 -0.103 0.803 32.64 0.789 2.092 0.920 
F3 7.684 0.953 -0.060 0.886 26.92 0.784 2.138 0.93 
F4 8.318 0.952 -0.074 0.833 29.05 0.778 2.091 0.952 
F5 6.379 0.951 -0.042 0.925 22.37 0.783 2.122 0.938 
F6 6.946 0.949 -0.048 0.911 24.32 0.780 2.137 0.940 
F7 7.942 0.950 -0.066 0.850 27.81 0.781 2.076 0.923 
F8 9.139 0.942 -0.089 0.880 32.13 0.780 2.198 0.920 
   
6.9. STABILITY STUDY 
The selected formulation (F2) was found to be stable upon 
storage for 3 months. No change was observed in the 
appearance, hardness and average weight of the tablet. 
Also no significant change was observed in the in-vitro 
release of the drug. 
CONCLUSION 
From the above results we can conclude that Mesalazine 
formulations prepared with HPMC K4M, HPMC K 15M 
and crosspovidone showed acceptable properties like 
friability, weight variation, hardness etc and in-vitro drug 
release which remained unchanged upon storage for 3 
months. However, HPMC K4M, HPMC K15M and 
crosspovidone (2.4%) based Mesalazine tablets with the 
formulation code F2 proved to be the formula of choice, 
since it showed the highest drug release and lag time when 
compared to the marketed formulation, Asacol. So, 
Mesalazine tablets can be used in sustained delayed drug 
delivery in treatment of ulcerative colitis so as to reduce 
the side effects of drug in stomach and also to reduce the 
dosing frequency of the drug. 
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